Retrospective Analysis of the Renoprotective Effects of Long-Term Use of Six Types of Sodium-Glucose Cotransporter 2 Inhibitors in Japanese Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease
Sodium-glucose cotransporter 2 inhibitors (SGLT2is) provide renal protection in patients with type 2 diabetes mellitus (T2DM). The aim of this study was to elucidate the renal effects of long-term use of six types of SGLT2is in Japanese patients with T2DM and chronic kidney disease (CKD). The Kanaga...
Gespeichert in:
| Veröffentlicht in: | Diabetes technology & therapeutics 2021-02, Vol.23 (2), p.110-119 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 119 |
|---|---|
| container_issue | 2 |
| container_start_page | 110 |
| container_title | Diabetes technology & therapeutics |
| container_volume | 23 |
| creator | Kobayashi, Kazuo Toyoda, Masao Hatori, Nobuo Saito, Nobumichi Kanaoka, Tomohiko Sakai, Hiroyuki Furuki, Takayuki Umezono, Tomoya Ito, Shun Suzuki, Daisuke Takeda, Hiroshi Minagawa, Fuyuki Degawa, Hisakazu Yamamoto, Hareaki Machimura, Hideo Chin, Keiichi Hishiki, Toshimasa Takihata, Masahiro Aoyama, Kouta Umezawa, Shinichi Minamisawa, Kohsuke Aoyama, Togo Hamada, Yoshiro Suzuki, Yoshiro Hayashi, Masahiro Hatori, Yutaka Sato, Kazuyoshi Miyakawa, Masaaki Tamura, Kouichi Kanamori, Akira |
| description | Sodium-glucose cotransporter 2 inhibitors (SGLT2is) provide renal protection in patients with type 2 diabetes mellitus (T2DM). The aim of this study was to elucidate the renal effects of long-term use of six types of SGLT2is in Japanese patients with T2DM and chronic kidney disease (CKD).
The Kanagawa Physicians Association maintains a registry of patients who visit their 31 clinics. We retrieved clinical data of patients with T2DM and CKD who were prescribed with SGLT2is for >1 year.
A total of 763 patients with a median treatment duration of 33 months were included. The logarithmic value of urine albumin-creatinine ratio (LNACR) decreased significantly from 1.60 ± 0.65 to 1.51 ± 0.67. The multiple linear regression analysis revealed that the LNACR at the initiation of treatment, change in (Δ) diastolic blood pressure, and Δ hemoglobin A1c were independently correlated with ΔLNACR (
|
| doi_str_mv | 10.1089/dia.2020.0165 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2428555318</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2490770860</sourcerecordid><originalsourceid>FETCH-LOGICAL-c321t-7d8d6302445a06fbe93e5adaf43ba65ebeb78d51bd938c1e7f2e7a96e71a7e083</originalsourceid><addsrcrecordid>eNpdkUtv3CAURlHVqnkuu62QusnGEx6DsZfRNK9molbJZG1hc90hssEFnGR-ZP5T8WTaRVYgvqNP3HsQ-kLJjJKiPNVGzRhhZEZoLj6gfSqEzApR8o_TnZGspCLfQwchPBJCJGf0M9rjTDLKmNxHr3cQvQsDNNE8AT6zqtsEE7BrcVwDvgPrBu_iLj5v23Tbpktnf2cr8D1-CDA93JsXvNoMsE3vnTZjn112Y-NSvHDRKxsG5yN4zPC1XZvaROcDNhb_UIOykLBfKhqwqf_ZxPW2LLHfjaohptpb6DoTx4CV1Xix9s6aBt8YbWGToAAqwBH61KouwPHuPEQPF-erxVW2_Hl5vThbZk2aP2ZSFzrnhM3nQpG8raHkIJRW7ZzXKhdQQy0LLWitS140FGTLQKoyB0mVBFLwQ3Ty1pt282eEEKvehCb9L83hxlCxOSuEEJxO6Ld36KMbfVrzRJVESlLkJFHZG9UkGcFDWw3e9MpvKkqqyXOVPFeT52rynPivu9ax7kH_p_-J5X8BDwemwQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2490770860</pqid></control><display><type>article</type><title>Retrospective Analysis of the Renoprotective Effects of Long-Term Use of Six Types of Sodium-Glucose Cotransporter 2 Inhibitors in Japanese Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease</title><source>Alma/SFX Local Collection</source><creator>Kobayashi, Kazuo ; Toyoda, Masao ; Hatori, Nobuo ; Saito, Nobumichi ; Kanaoka, Tomohiko ; Sakai, Hiroyuki ; Furuki, Takayuki ; Umezono, Tomoya ; Ito, Shun ; Suzuki, Daisuke ; Takeda, Hiroshi ; Minagawa, Fuyuki ; Degawa, Hisakazu ; Yamamoto, Hareaki ; Machimura, Hideo ; Chin, Keiichi ; Hishiki, Toshimasa ; Takihata, Masahiro ; Aoyama, Kouta ; Umezawa, Shinichi ; Minamisawa, Kohsuke ; Aoyama, Togo ; Hamada, Yoshiro ; Suzuki, Yoshiro ; Hayashi, Masahiro ; Hatori, Yutaka ; Sato, Kazuyoshi ; Miyakawa, Masaaki ; Tamura, Kouichi ; Kanamori, Akira</creator><creatorcontrib>Kobayashi, Kazuo ; Toyoda, Masao ; Hatori, Nobuo ; Saito, Nobumichi ; Kanaoka, Tomohiko ; Sakai, Hiroyuki ; Furuki, Takayuki ; Umezono, Tomoya ; Ito, Shun ; Suzuki, Daisuke ; Takeda, Hiroshi ; Minagawa, Fuyuki ; Degawa, Hisakazu ; Yamamoto, Hareaki ; Machimura, Hideo ; Chin, Keiichi ; Hishiki, Toshimasa ; Takihata, Masahiro ; Aoyama, Kouta ; Umezawa, Shinichi ; Minamisawa, Kohsuke ; Aoyama, Togo ; Hamada, Yoshiro ; Suzuki, Yoshiro ; Hayashi, Masahiro ; Hatori, Yutaka ; Sato, Kazuyoshi ; Miyakawa, Masaaki ; Tamura, Kouichi ; Kanamori, Akira</creatorcontrib><description><![CDATA[Sodium-glucose cotransporter 2 inhibitors (SGLT2is) provide renal protection in patients with type 2 diabetes mellitus (T2DM). The aim of this study was to elucidate the renal effects of long-term use of six types of SGLT2is in Japanese patients with T2DM and chronic kidney disease (CKD).
The Kanagawa Physicians Association maintains a registry of patients who visit their 31 clinics. We retrieved clinical data of patients with T2DM and CKD who were prescribed with SGLT2is for >1 year.
A total of 763 patients with a median treatment duration of 33 months were included. The logarithmic value of urine albumin-creatinine ratio (LNACR) decreased significantly from 1.60 ± 0.65 to 1.51 ± 0.67. The multiple linear regression analysis revealed that the LNACR at the initiation of treatment, change in (Δ) diastolic blood pressure, and Δ hemoglobin A1c were independently correlated with ΔLNACR (
< 0.001). The decrease in the LNACR was significantly smaller in the patients with estimated glomerular filtration rate (eGFR) [mL/(min ·1.73 m
)] of <60 (
< 0.05). The eGFR decreased from 77.4 ± 22.3 to 72.7 ± 22.5 mL/(min ·1.73 m
) (
< 0.001). The multiple linear regression analysis showed that the LNACR at the initiation of treatment, Δbody weight at the previous survey, ΔeGFR at the previous survey, and the eGFR at the initiation of treatment correlated independently with ΔeGFR during the maintenance period (
< 0.001). Greater changes in the eGFR during the maintenance period were observed in the patients with macroalbuminuria or eGFR of <60 (
< 0.01).
The study confirmed that the long-term use of six types of SGLT2i improved the albumin-creatinine ratio (ACR), although the eGFR gradually decreased during the treatment. The change in the ACR was significantly smaller in the patients with eGFR of <60 mL/(min ·1.73 m
) than in those with eGFR of >60 mL/(min ·1.73 m
). However, this was a retrospective observational study; further studies are needed to formulate final conclusions.]]></description><identifier>ISSN: 1520-9156</identifier><identifier>EISSN: 1557-8593</identifier><identifier>DOI: 10.1089/dia.2020.0165</identifier><identifier>PMID: 32721227</identifier><language>eng</language><publisher>United States: Mary Ann Liebert, Inc</publisher><subject>Clinical outcomes ; Creatinine ; Diabetes ; Inhibitor drugs ; Kidney diseases ; Longitudinal studies ; Regression analysis</subject><ispartof>Diabetes technology & therapeutics, 2021-02, Vol.23 (2), p.110-119</ispartof><rights>Copyright Mary Ann Liebert, Inc. Feb 2021</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c321t-7d8d6302445a06fbe93e5adaf43ba65ebeb78d51bd938c1e7f2e7a96e71a7e083</citedby><cites>FETCH-LOGICAL-c321t-7d8d6302445a06fbe93e5adaf43ba65ebeb78d51bd938c1e7f2e7a96e71a7e083</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32721227$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kobayashi, Kazuo</creatorcontrib><creatorcontrib>Toyoda, Masao</creatorcontrib><creatorcontrib>Hatori, Nobuo</creatorcontrib><creatorcontrib>Saito, Nobumichi</creatorcontrib><creatorcontrib>Kanaoka, Tomohiko</creatorcontrib><creatorcontrib>Sakai, Hiroyuki</creatorcontrib><creatorcontrib>Furuki, Takayuki</creatorcontrib><creatorcontrib>Umezono, Tomoya</creatorcontrib><creatorcontrib>Ito, Shun</creatorcontrib><creatorcontrib>Suzuki, Daisuke</creatorcontrib><creatorcontrib>Takeda, Hiroshi</creatorcontrib><creatorcontrib>Minagawa, Fuyuki</creatorcontrib><creatorcontrib>Degawa, Hisakazu</creatorcontrib><creatorcontrib>Yamamoto, Hareaki</creatorcontrib><creatorcontrib>Machimura, Hideo</creatorcontrib><creatorcontrib>Chin, Keiichi</creatorcontrib><creatorcontrib>Hishiki, Toshimasa</creatorcontrib><creatorcontrib>Takihata, Masahiro</creatorcontrib><creatorcontrib>Aoyama, Kouta</creatorcontrib><creatorcontrib>Umezawa, Shinichi</creatorcontrib><creatorcontrib>Minamisawa, Kohsuke</creatorcontrib><creatorcontrib>Aoyama, Togo</creatorcontrib><creatorcontrib>Hamada, Yoshiro</creatorcontrib><creatorcontrib>Suzuki, Yoshiro</creatorcontrib><creatorcontrib>Hayashi, Masahiro</creatorcontrib><creatorcontrib>Hatori, Yutaka</creatorcontrib><creatorcontrib>Sato, Kazuyoshi</creatorcontrib><creatorcontrib>Miyakawa, Masaaki</creatorcontrib><creatorcontrib>Tamura, Kouichi</creatorcontrib><creatorcontrib>Kanamori, Akira</creatorcontrib><title>Retrospective Analysis of the Renoprotective Effects of Long-Term Use of Six Types of Sodium-Glucose Cotransporter 2 Inhibitors in Japanese Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease</title><title>Diabetes technology & therapeutics</title><addtitle>Diabetes Technol Ther</addtitle><description><![CDATA[Sodium-glucose cotransporter 2 inhibitors (SGLT2is) provide renal protection in patients with type 2 diabetes mellitus (T2DM). The aim of this study was to elucidate the renal effects of long-term use of six types of SGLT2is in Japanese patients with T2DM and chronic kidney disease (CKD).
The Kanagawa Physicians Association maintains a registry of patients who visit their 31 clinics. We retrieved clinical data of patients with T2DM and CKD who were prescribed with SGLT2is for >1 year.
A total of 763 patients with a median treatment duration of 33 months were included. The logarithmic value of urine albumin-creatinine ratio (LNACR) decreased significantly from 1.60 ± 0.65 to 1.51 ± 0.67. The multiple linear regression analysis revealed that the LNACR at the initiation of treatment, change in (Δ) diastolic blood pressure, and Δ hemoglobin A1c were independently correlated with ΔLNACR (
< 0.001). The decrease in the LNACR was significantly smaller in the patients with estimated glomerular filtration rate (eGFR) [mL/(min ·1.73 m
)] of <60 (
< 0.05). The eGFR decreased from 77.4 ± 22.3 to 72.7 ± 22.5 mL/(min ·1.73 m
) (
< 0.001). The multiple linear regression analysis showed that the LNACR at the initiation of treatment, Δbody weight at the previous survey, ΔeGFR at the previous survey, and the eGFR at the initiation of treatment correlated independently with ΔeGFR during the maintenance period (
< 0.001). Greater changes in the eGFR during the maintenance period were observed in the patients with macroalbuminuria or eGFR of <60 (
< 0.01).
The study confirmed that the long-term use of six types of SGLT2i improved the albumin-creatinine ratio (ACR), although the eGFR gradually decreased during the treatment. The change in the ACR was significantly smaller in the patients with eGFR of <60 mL/(min ·1.73 m
) than in those with eGFR of >60 mL/(min ·1.73 m
). However, this was a retrospective observational study; further studies are needed to formulate final conclusions.]]></description><subject>Clinical outcomes</subject><subject>Creatinine</subject><subject>Diabetes</subject><subject>Inhibitor drugs</subject><subject>Kidney diseases</subject><subject>Longitudinal studies</subject><subject>Regression analysis</subject><issn>1520-9156</issn><issn>1557-8593</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNpdkUtv3CAURlHVqnkuu62QusnGEx6DsZfRNK9molbJZG1hc90hssEFnGR-ZP5T8WTaRVYgvqNP3HsQ-kLJjJKiPNVGzRhhZEZoLj6gfSqEzApR8o_TnZGspCLfQwchPBJCJGf0M9rjTDLKmNxHr3cQvQsDNNE8AT6zqtsEE7BrcVwDvgPrBu_iLj5v23Tbpktnf2cr8D1-CDA93JsXvNoMsE3vnTZjn112Y-NSvHDRKxsG5yN4zPC1XZvaROcDNhb_UIOykLBfKhqwqf_ZxPW2LLHfjaohptpb6DoTx4CV1Xix9s6aBt8YbWGToAAqwBH61KouwPHuPEQPF-erxVW2_Hl5vThbZk2aP2ZSFzrnhM3nQpG8raHkIJRW7ZzXKhdQQy0LLWitS140FGTLQKoyB0mVBFLwQ3Ty1pt282eEEKvehCb9L83hxlCxOSuEEJxO6Ld36KMbfVrzRJVESlLkJFHZG9UkGcFDWw3e9MpvKkqqyXOVPFeT52rynPivu9ax7kH_p_-J5X8BDwemwQ</recordid><startdate>202102</startdate><enddate>202102</enddate><creator>Kobayashi, Kazuo</creator><creator>Toyoda, Masao</creator><creator>Hatori, Nobuo</creator><creator>Saito, Nobumichi</creator><creator>Kanaoka, Tomohiko</creator><creator>Sakai, Hiroyuki</creator><creator>Furuki, Takayuki</creator><creator>Umezono, Tomoya</creator><creator>Ito, Shun</creator><creator>Suzuki, Daisuke</creator><creator>Takeda, Hiroshi</creator><creator>Minagawa, Fuyuki</creator><creator>Degawa, Hisakazu</creator><creator>Yamamoto, Hareaki</creator><creator>Machimura, Hideo</creator><creator>Chin, Keiichi</creator><creator>Hishiki, Toshimasa</creator><creator>Takihata, Masahiro</creator><creator>Aoyama, Kouta</creator><creator>Umezawa, Shinichi</creator><creator>Minamisawa, Kohsuke</creator><creator>Aoyama, Togo</creator><creator>Hamada, Yoshiro</creator><creator>Suzuki, Yoshiro</creator><creator>Hayashi, Masahiro</creator><creator>Hatori, Yutaka</creator><creator>Sato, Kazuyoshi</creator><creator>Miyakawa, Masaaki</creator><creator>Tamura, Kouichi</creator><creator>Kanamori, Akira</creator><general>Mary Ann Liebert, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>202102</creationdate><title>Retrospective Analysis of the Renoprotective Effects of Long-Term Use of Six Types of Sodium-Glucose Cotransporter 2 Inhibitors in Japanese Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease</title><author>Kobayashi, Kazuo ; Toyoda, Masao ; Hatori, Nobuo ; Saito, Nobumichi ; Kanaoka, Tomohiko ; Sakai, Hiroyuki ; Furuki, Takayuki ; Umezono, Tomoya ; Ito, Shun ; Suzuki, Daisuke ; Takeda, Hiroshi ; Minagawa, Fuyuki ; Degawa, Hisakazu ; Yamamoto, Hareaki ; Machimura, Hideo ; Chin, Keiichi ; Hishiki, Toshimasa ; Takihata, Masahiro ; Aoyama, Kouta ; Umezawa, Shinichi ; Minamisawa, Kohsuke ; Aoyama, Togo ; Hamada, Yoshiro ; Suzuki, Yoshiro ; Hayashi, Masahiro ; Hatori, Yutaka ; Sato, Kazuyoshi ; Miyakawa, Masaaki ; Tamura, Kouichi ; Kanamori, Akira</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c321t-7d8d6302445a06fbe93e5adaf43ba65ebeb78d51bd938c1e7f2e7a96e71a7e083</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Clinical outcomes</topic><topic>Creatinine</topic><topic>Diabetes</topic><topic>Inhibitor drugs</topic><topic>Kidney diseases</topic><topic>Longitudinal studies</topic><topic>Regression analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kobayashi, Kazuo</creatorcontrib><creatorcontrib>Toyoda, Masao</creatorcontrib><creatorcontrib>Hatori, Nobuo</creatorcontrib><creatorcontrib>Saito, Nobumichi</creatorcontrib><creatorcontrib>Kanaoka, Tomohiko</creatorcontrib><creatorcontrib>Sakai, Hiroyuki</creatorcontrib><creatorcontrib>Furuki, Takayuki</creatorcontrib><creatorcontrib>Umezono, Tomoya</creatorcontrib><creatorcontrib>Ito, Shun</creatorcontrib><creatorcontrib>Suzuki, Daisuke</creatorcontrib><creatorcontrib>Takeda, Hiroshi</creatorcontrib><creatorcontrib>Minagawa, Fuyuki</creatorcontrib><creatorcontrib>Degawa, Hisakazu</creatorcontrib><creatorcontrib>Yamamoto, Hareaki</creatorcontrib><creatorcontrib>Machimura, Hideo</creatorcontrib><creatorcontrib>Chin, Keiichi</creatorcontrib><creatorcontrib>Hishiki, Toshimasa</creatorcontrib><creatorcontrib>Takihata, Masahiro</creatorcontrib><creatorcontrib>Aoyama, Kouta</creatorcontrib><creatorcontrib>Umezawa, Shinichi</creatorcontrib><creatorcontrib>Minamisawa, Kohsuke</creatorcontrib><creatorcontrib>Aoyama, Togo</creatorcontrib><creatorcontrib>Hamada, Yoshiro</creatorcontrib><creatorcontrib>Suzuki, Yoshiro</creatorcontrib><creatorcontrib>Hayashi, Masahiro</creatorcontrib><creatorcontrib>Hatori, Yutaka</creatorcontrib><creatorcontrib>Sato, Kazuyoshi</creatorcontrib><creatorcontrib>Miyakawa, Masaaki</creatorcontrib><creatorcontrib>Tamura, Kouichi</creatorcontrib><creatorcontrib>Kanamori, Akira</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetes technology & therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kobayashi, Kazuo</au><au>Toyoda, Masao</au><au>Hatori, Nobuo</au><au>Saito, Nobumichi</au><au>Kanaoka, Tomohiko</au><au>Sakai, Hiroyuki</au><au>Furuki, Takayuki</au><au>Umezono, Tomoya</au><au>Ito, Shun</au><au>Suzuki, Daisuke</au><au>Takeda, Hiroshi</au><au>Minagawa, Fuyuki</au><au>Degawa, Hisakazu</au><au>Yamamoto, Hareaki</au><au>Machimura, Hideo</au><au>Chin, Keiichi</au><au>Hishiki, Toshimasa</au><au>Takihata, Masahiro</au><au>Aoyama, Kouta</au><au>Umezawa, Shinichi</au><au>Minamisawa, Kohsuke</au><au>Aoyama, Togo</au><au>Hamada, Yoshiro</au><au>Suzuki, Yoshiro</au><au>Hayashi, Masahiro</au><au>Hatori, Yutaka</au><au>Sato, Kazuyoshi</au><au>Miyakawa, Masaaki</au><au>Tamura, Kouichi</au><au>Kanamori, Akira</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Retrospective Analysis of the Renoprotective Effects of Long-Term Use of Six Types of Sodium-Glucose Cotransporter 2 Inhibitors in Japanese Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease</atitle><jtitle>Diabetes technology & therapeutics</jtitle><addtitle>Diabetes Technol Ther</addtitle><date>2021-02</date><risdate>2021</risdate><volume>23</volume><issue>2</issue><spage>110</spage><epage>119</epage><pages>110-119</pages><issn>1520-9156</issn><eissn>1557-8593</eissn><abstract><![CDATA[Sodium-glucose cotransporter 2 inhibitors (SGLT2is) provide renal protection in patients with type 2 diabetes mellitus (T2DM). The aim of this study was to elucidate the renal effects of long-term use of six types of SGLT2is in Japanese patients with T2DM and chronic kidney disease (CKD).
The Kanagawa Physicians Association maintains a registry of patients who visit their 31 clinics. We retrieved clinical data of patients with T2DM and CKD who were prescribed with SGLT2is for >1 year.
A total of 763 patients with a median treatment duration of 33 months were included. The logarithmic value of urine albumin-creatinine ratio (LNACR) decreased significantly from 1.60 ± 0.65 to 1.51 ± 0.67. The multiple linear regression analysis revealed that the LNACR at the initiation of treatment, change in (Δ) diastolic blood pressure, and Δ hemoglobin A1c were independently correlated with ΔLNACR (
< 0.001). The decrease in the LNACR was significantly smaller in the patients with estimated glomerular filtration rate (eGFR) [mL/(min ·1.73 m
)] of <60 (
< 0.05). The eGFR decreased from 77.4 ± 22.3 to 72.7 ± 22.5 mL/(min ·1.73 m
) (
< 0.001). The multiple linear regression analysis showed that the LNACR at the initiation of treatment, Δbody weight at the previous survey, ΔeGFR at the previous survey, and the eGFR at the initiation of treatment correlated independently with ΔeGFR during the maintenance period (
< 0.001). Greater changes in the eGFR during the maintenance period were observed in the patients with macroalbuminuria or eGFR of <60 (
< 0.01).
The study confirmed that the long-term use of six types of SGLT2i improved the albumin-creatinine ratio (ACR), although the eGFR gradually decreased during the treatment. The change in the ACR was significantly smaller in the patients with eGFR of <60 mL/(min ·1.73 m
) than in those with eGFR of >60 mL/(min ·1.73 m
). However, this was a retrospective observational study; further studies are needed to formulate final conclusions.]]></abstract><cop>United States</cop><pub>Mary Ann Liebert, Inc</pub><pmid>32721227</pmid><doi>10.1089/dia.2020.0165</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1520-9156 |
| ispartof | Diabetes technology & therapeutics, 2021-02, Vol.23 (2), p.110-119 |
| issn | 1520-9156 1557-8593 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2428555318 |
| source | Alma/SFX Local Collection |
| subjects | Clinical outcomes Creatinine Diabetes Inhibitor drugs Kidney diseases Longitudinal studies Regression analysis |
| title | Retrospective Analysis of the Renoprotective Effects of Long-Term Use of Six Types of Sodium-Glucose Cotransporter 2 Inhibitors in Japanese Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T07%3A14%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Retrospective%20Analysis%20of%20the%20Renoprotective%20Effects%20of%20Long-Term%20Use%20of%20Six%20Types%20of%20Sodium-Glucose%20Cotransporter%202%20Inhibitors%20in%20Japanese%20Patients%20with%20Type%202%20Diabetes%20Mellitus%20and%20Chronic%20Kidney%20Disease&rft.jtitle=Diabetes%20technology%20&%20therapeutics&rft.au=Kobayashi,%20Kazuo&rft.date=2021-02&rft.volume=23&rft.issue=2&rft.spage=110&rft.epage=119&rft.pages=110-119&rft.issn=1520-9156&rft.eissn=1557-8593&rft_id=info:doi/10.1089/dia.2020.0165&rft_dat=%3Cproquest_cross%3E2490770860%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2490770860&rft_id=info:pmid/32721227&rfr_iscdi=true |